News Article

ShuntCheck® Principal Investigator Presents Favorable Interim Clinical Results
Date: Jan 14, 2016
Source: Company Data ( click here to go to the source)

Featured firm in this article: NeuroDx Development LLC of Bensalem, PA



PRINCETON, NJ January 14, 2016 -- Dr. Joseph R. Madsen, Pediatric Neurosurgeon at Boston Children’s Hospital and the Principal Investigator of the ShuntCheck Pediatric Outcomes Validation Study, presented interim findings (280 patients) at the American Society of Pediatric Neurosurgeons (ASPN) annual meeting.

ShuntCheck, which uses thermal dilution technology to detect flow in the CSF shunts of hydrocephalus patients, achieved its two clinical study endpoints. The prospective, blinded multi-center study demonstrated that ShuntCheck was equal to neuroimaging in ruling out shunt obstruction in symptomatic pediatric patients clinically judged "unlikely to require surgery". It also showed that concordant ShuntCheck-plus-Imaging results were superior to Imaging results.

"These results suggest that adding ShuntCheck to the shunt malfunction diagnostic protocol can reduce the need for CT Scans, Admissions for Observation and invasive tests" said Dr. Madsen.

"We are very grateful to Dr. Madsen for his leadership and to investigators at nine other US Children's Hospitals for their dedication to this study," said Frederick J Fritz, NeuroDx founder and CEO. "These positive interim results support the use of ShuntCheck as a diagnostic tool for physicians who care for children with hydrocephalus," he said.

NeuroDx Development (www.neurodx.com) is a privately held diagnostic device company focused on addressing unmet clinical needs in the neurosurgery market. NeuroDx is headquartered in Princeton NJ.